Since mid-2016, the JiVitA Project in rural Bangladesh has been carefully tracking all women, pregnancies and births within a 450 sq km area as part of the mCARE-II randomized controlled trial. As part of this work, 100 Government of Bangladesh community health workers were randomized to either use the mCARE-II digital health intervention to guide their provision of reproductive, maternal, and essential newborn health services to their large catchment populations versus standard of care procedures. Designed to independently measure the true population denominator of eligible clients and follow them prospectively to assess performance of intervention and the control CHWs who are using it, mCARE-II is one of the largest digital health trials of its kind. Powered to assess possible changes in perinatal mortality, over 24,000 pregnancies have been enumerated, enrolled and followed. Perinatal mortality is the trial's primary outcome, along with the coverage and timeliness of critical ANC, PNC and ENC services to these women and their neonates. The mCARE-II randomized controlled trial will be presented during this preformed panel, including the analytic roadmap and challenges/mitigation strategies in training, monitoring and exposure/outcome measurement. The panel will first outline the 1) mCARE-II Trial Methods, Design and Interventions, will then address the extensive 2) Training, Standardization and Monitoring of Implementation Fidelity and will conclude with a presentation of the analytic strategy and available data insights, including 3) Intervention coverage, FHW performance variability, ANC/PNC coverage, timeliness, perinatal mortality and other outcomes.
Since mid-2016, the JiVitA Project in rural Bangladesh has been carefully tracking all women, pregnancies and births within a 450 sq km area as part of the mCARE-II randomized controlled trial. As part of this work, 100 Government of Bangladesh community health workers were randomized to either use the mCARE-II digital health intervention to guide their provision of reproductive, maternal, and essential newborn health services to their large catchment populations versus standard of care procedures. Designed to independently measure the true population denominator of eligible clients and follow them prospectively to assess performance of intervention and the control CHWs who are using it, mCARE-II is one of the largest digital health trials of its kind. Powered to assess possible changes in perinatal mortality, over 24,000 pregnancies have been enumerated, enrolled and followed. Perinatal mortality is the trial's primary outcome, along with the coverage and timeliness of critical ANC, PNC and ENC services to these women and their neonates. The mCARE-II randomized controlled trial will be presented during this preformed panel, including the analytic roadmap and challenges/mitigation strategies in training, monitoring and exposure/outcome measurement. The panel will first outline the 1) mCARE-II Trial Methods, Design and Interventions, will then address the extensive 2) Training, Standardization and Monitoring of Implementation Fidelity and will conclude with a presentation of the analytic strategy and available data insights, including 3) Intervention coverage, FHW performance variability, ANC/PNC coverage, timeliness, perinatal mortality and other outcomes.
White Oak B 2019 Global Digital Health Forum gdhf2019@dryfta.orgTechnical Issues?
If you're experiencing playback problems, try adjusting the quality or refreshing the page.
Questions for Speakers?
Use the Q&A tab to submit questions that may be addressed in follow-up sessions.
